CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Total revenues	$ 311,770	$ 380,724	$ 455,897
Costs and expenses:
Cost of sales (excluding amortization of intangible assets)	18,476	72,598	87,414
Research and development expenses	8,042	13,718	32,631
Acquired in-process research and development	0	24,900	0
Selling, general and administrative expenses	119,218	195,696	204,498
Amortization of intangible assets	101,774	102,745	106,845
Restructuring charges	20,601	13,247	0
Total costs and expenses	268,111	422,904	431,388
Income (loss) from operations	43,659	(42,180)	24,509
Other income (expense):
Litigation settlement	62,000	0	0
Gain on divestiture of Lazanda	0	17,064	0
Interest and other income	1,197	681	485
Loss on prepayment of Senior Notes	0	(5,938)	(5,777)
Interest expense	(68,881)	(73,552)	(83,719)
Income (loss) before income taxes	37,975	(103,925)	(64,502)
Income tax (expense) benefit	(1,067)	1,429	(24,218)
Net income (loss)	$ 36,908	$ (102,496)	$ (88,720)
Basic net income (loss) per share (in dollars per share)	$ 0.58	$ (1.63)	$ (1.45)
Diluted net income (loss) per share (in dollars per share)	$ 0.57	$ (1.63)	$ (1.45)
Shares used in computing basic net income (loss) per share (in shares)	63,794	62,702	61,297
Shares used in computing diluted net income (loss) per share (in shares)	64,208	62,702	61,297
Product sales, net
Revenues:
Total revenues	$ 129,966	$ 379,880	$ 455,066
Commercialization agreement, net
Revenues:
Total revenues	155,743	0	0
Royalties and milestones
Revenues:
Total revenues	$ 26,061	$ 844	$ 831